Výsledky vyhledávání - "C. Álvarez-Reguera"

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

AB1147 COVID 19 INFECTION IN PATIENTS WITH RHEUMATIC IMMUNE-MEDIATED DISEASES IN A SINGLE UNIVERSITY HOSPITAL. MATCHED CASE-CONTROL STUDY

Autor: D. Martínez-López, D. Prieto-Peña, F. Benavides-Villanueva, L. Sanchez-Bilbao, C. Corrales-Selaya, A. Herrero-Morant, C. Álvarez-Reguera, M. Trigueros-Vazquez, R. Wallman, M. A. González-Gay, R. Blanco

Publikováno v: Annals of the Rheumatic Diseases. 81:1690-1691

BackgroundCOVID19 may present different degrees of severity. It is generally thought that viral infections in patients with rheumatic inflammatory diseases (R-IMID) or receiving immunosuppressive treatment tend to present more severe disease. However

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::20266aec7df4fafa5c926d0248981f7e
https://doi.org/10.1136/annrheumdis-2022-eular.3808

Zobrazit plný text záznamu

AB1311 INCREASED RISK OF HEPATOTOXICITY WITH DMARDS IN PATIENTS WITH PREVIOUS LIVER TOXICITY WITH ISONIAZID. STUDY IN A SINGLE UNIVERSITY HOSPITAL

Autor: D. Martínez-López, J. Osorio-Chavez, V. Portilla, C. Álvarez-Reguera, A. Herrero-Morant, L. Sanchez-Bilbao, I. Gonzalez-Mazon, M. A. González-Gay, R. Blanco

Publikováno v: Annals of the Rheumatic Diseases. 81:1762-1763

BackgroundIsoniazid (INH) is used to treat latent tuberculosis infection (LTBI), and hepatotoxicity is one of the most frequent adverse effect. Several Disease-modifying drugs (DMARDs) can also cause hepatotoxicity. Many patients with rheumatic immun

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::dec829d2ea2737ee51ad6c292d69b932
https://doi.org/10.1136/annrheumdis-2022-eular.3962

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

AB1314 JANUS KINASE INHIBITORS IN REFRACTORY AUTOINFLAMMATORY SYNDROMES. TWO CASE REPORTS AND LITERATURE REVIEW

Autor: C. Álvarez-Reguera, D. Prieto-Peña, L. Sanchez-Bilbao, A. Herrero-Morant, D. Martínez-López, M. Á. González-Gay, R. Blanco

Publikováno v: Annals of the Rheumatic Diseases. 81:1764.1-1764

BackgroundAutoinflammatory syndromes are characterized by dysregulation of innate immunity and recurrent episodes of fever, cutaneous and other. Janus Kinase inhibitors (JAKINIB) may inhibit innate and acquired immunity. They have been approved in se

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::291aaa50ae3fa2210d0d009f1abe36ba
https://doi.org/10.1136/annrheumdis-2022-eular.4014

Zobrazit plný text záznamu

AB1310 JANUS KINASE INHIBITORS IN SEVERE AND REFRACTORY INFLAMMATORY OCULAR PATHOLOGY. CASES REPORTS AND LITERATURE REVIEW

Autor: L. Sanchez-Bilbao, V. Calvo-Río, J. L. Martín-Varillas, I. Torre-Salaberri, O. Maiz, E. Beltrán, J. L. Álvarez Vega, C. Álvarez-Reguera, R. Demetrio-Pablo, M. A. González-Gay, R. Blanco

Publikováno v: Annals of the Rheumatic Diseases. 81:1761.2-1762

BackgroundInflammatory ocular pathology (IOP) includes internal and external involvement. IOP may be severe ocular conditions refractory to conventional immunosuppressants and even biological therapy. Janus Kinase inhibitors (JAKINIB) had shown effic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c789a53a7792aa6f7b2a99c92cc69212
https://doi.org/10.1136/annrheumdis-2022-eular.3937

Zobrazit plný text záznamu

AB1320 JAK2 (V617F) MUTATION AND ASSOCIATION TO RHEUMATOLOGICAL DISEASES TREATMENT. STUDY OF 130 PATIENTS FROM A SINGLE UNIVERSITY HOSPITAL

Autor: C. Álvarez-Reguera, L. Sanchez-Bilbao, S. Fernández López, A. Batlle-López, A. Herrero-Morant, D. Martínez-López, M. Á. González-Gay, R. Blanco

Publikováno v: Annals of the Rheumatic Diseases. 81:1766.2-1767

BackgroundJanus Kinases (JAK) can promote cytokine production in immune and hematopoietic cells. The JAK-2 (V617F) mutation is the most frequently detected mutation in myeloproliferative neoplasms (MPN) which include essential thrombocythemia (ET), p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5bf5d5f98f451a9eb735306aa3cd8d02
https://doi.org/10.1136/annrheumdis-2022-eular.4864

Zobrazit plný text záznamu

POS1347 BIOLOGICAL THERAPY IN NEUROSARCOIDOSIS. STUDY OF 30 PATIENTS FROM A SERIES OF 234 SYSTEMIC SARCOIDOSIS FROM A UNIVERSITY HOSPITAL

Autor: A. Herrero-Morant, D. Martínez-López, L. Sanchez-Bilbao, I. Gonzalez-Mazon, J. L. Martín-Varillas, R. Fernández Ramón, C. Álvarez-Reguera, M. Á. González-Gay, R. Blanco

Publikováno v: Annals of the Rheumatic Diseases. 81:1011.2-1012

BackgroundNeurosarcoidosis (NS) is a severe complication of sarcoidosis [1,2]. NS may be classified according to several subtypes [1]. Data on therapy, including biological therapy (BT) is scarce.ObjectivesTo assess efficacy and safety of BT in refra

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::39d1d8f1eac2d3a410f5b7e284cfb582
https://doi.org/10.1136/annrheumdis-2022-eular.2878

Zobrazit plný text záznamu

POS0828 BIOLOGIC THERAPY IN REFRACTORY PARENCHYMAL AND NON-PARENCHYMAL NEUROBEHÇET DISEASE: NATIONAL MULTICENTER STUDY

Publikováno v: Annals of the Rheumatic Diseases. 81:704.3-705

BackgroundOcular and Neurobehçet’s Disease (NBD) are the most severe manifestations of Behcet’s disease (1-4). NBD can be classified as a) primary neural parenchymal lesions, also known as parenchymal NBD (p-NBD) or b) secondary to vascular invo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::857714b3bac2534b5074890a939665e9
https://doi.org/10.1136/annrheumdis-2022-eular.2681

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání